A novel study shows women who undergo surgical treatment for endometriosis have a lower risk of developing ovarian cancer. According to results published in Acta Obstetricia et Gynecologica Scandinavica, a journal of the Nordic Federation of Societies of Obstetrics and Gynecology, hormonal treatments for endometriosis did not lower ovarian cancer risk.
Endometriosis is a common, and often painful, gynecological disease where tissue normally found inside the uterus, grows elsewhere in the body. According to the World Health Organization this estrogen-dependent disease affects roughly 14% of women of childbearing age. The National Institutes of Health (NIH) estimates that more than 5.5 million women in North America have endometriosis, and if left untreated can cause infertility in up to 40% of women who are unable to conceive.
Prior research shows an increased risk of several cancers, including ovarian cancer, in women with endometriosis. Some studies have found a protective effect against ovarian cancer with surgical interventions, such as hysterectomy or tubal ligation. Lead author, Dr. Anna-Sofia Melin from the Karolinska Institute and Karolinska University Hospital in Stockholm, Sweden explains, “Patients with endometriosis are typically treated with hormones, or in more severe cases, with surgery. We wanted to expand understanding of ovarian cancer risk in women with endometriosis who had some type of surgery or hormone therapy.”
Using the National Swedish Patient Register, the team identified women diagnosed with endometriosis between 1969 and 2007. The National Swedish Cancer Register was then used to link women who were diagnosed with epithelial ovarian cancer at least one year following a diagnosis of endometriosis. Information on hormonal and surgical treatments was taken from medical records of the 220 women with endometriosis and ovarian cancer (cases) and 416 women with endometriosis only (controls).
Findings indicate a significant association between the surgical removal of an ovary (oophorectomy) and ovarian cancer risk. A significant link between ovarian cancer risk and radical removal of all visible endometriosis was also found. “Our study suggests that surgical removal of an ovary and removal of visible endometriosis protects women from developing ovarian cancer at a later point,” concludes Dr. Melin. “For women with endometriosis, the role of hormonal treatment and future ovarian cancer risk remains unclear and further investigation is warranted.”
Full citation: Hormonal and Surgical Treatments for Endometriosis and Risk of Epithelial Ovarian Cancer.” Anna-Sofia Melin, Cecilia Lundholm, Ninoa Malki, Marja-Liisa Swahn, Par Sparen and Agneta Bergqvist. Acta Obstetricia et Gynecologica Scandinavica; Published online: April 11, 2013 (DOI: 10.1111/aogs.12123)
About the Journal:
Acta Obstetricia et Gynecologica Scandinavica is the official scientific journal of the Nordic Federation of Societies of Obstetrics and Gynecology (NFOG). It is a clinically oriented journal that covers all aspects of obstetrics, gynecology and reproductive health, including perinatology, gynecologic endocrinology, female urology and gynecologic oncology. The journal is published in English and includes: editors´ messages, editorials, Acta commentaries, Acta reviews and original articles under the main categories of investigation, pregnancy, birth, fertility, infection, gynecology, gynecologic urology, oncology and surgery. The journal is published by Wiley on behalf of the NFOG. For more information, please visit http://wileyonlinelibrary.com/journal/aogs.
Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley’s global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia.